The results of the first clinical trial with the radiolabeled HER2-targeting affibody ABY-002 (DOTA ZHER2:342 pep2) in patients with recurrent breast cancer were very promising (EudraCT 2007 002530 11). The gene discussed is ERBB2; the disease is breast carcinoma.